CONMED Corp. 10-K Summary (Fiscal Year Ended Dec 29, 1995)
Business Context and Reporting Period
CONMED Corporation is a leading provider of advanced electrosurgical systems, ECG electrodes, and minimally-invasive surgery (MIS) instruments. The company operates three divisions: Electrosurgical Systems, Patient Care, and Minimally-Invasive Surgery. Approximately 85% of revenues are derived from single-use, disposable products. The reporting period covers the fiscal year ended December 29, 1995.
Key Financial Metrics
| Metric | 1995 | 1994 |
|---|---|---|
| Net Sales | $99,558,000 | $71,064,000 |
| Net Income | $10,863,000 | $5,416,000 |
| Earnings Per Share | $0.94 | $0.56 |
| Gross Margin | 47.4% | 45.4% |
| Operating Income | $18,754,000 | $8,934,000 |
| Cash Flow from Operations | $5,059,000 | $8,260,000 |
| Long-Term Debt | $26,340,000 | $6,875,000 |
| Working Capital | $37,350,000 | $18,159,000 |
| Total Assets | $119,403,000 | $62,104,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 40.1% to $99.6 million, driven primarily by the acquisitions of Birtcher Medical Systems (March 1995) and Master Medical Corporation (May 1995).
- Profitability: Net income doubled to $10.9 million. Gross margin improved to 47.4% due to manufacturing efficiencies and economies of scale from acquisitions.
- Debt Levels: Long-term debt increased significantly to $26.3 million (from $6.9 million) to finance acquisitions. Interest expense rose to $2.0 million.
- Cash Flow: Operating cash flow decreased to $5.1 million (from $8.3 million) despite higher net income, due to increased working capital requirements (accounts receivable and inventory) and the timing of tax payments.
- Balance Sheet: Total assets nearly doubled to $119.4 million, reflecting significant increases in goodwill ($41.4 million) and inventory ($20.9 million).
Outlook, Risks, and Unusual Items
- Acquisitions: The company signed an agreement in October 1995 to acquire New Dimensions in Medicine, Inc. (NDM) for approximately $32 million cash plus $5.1 million in liabilities. This deal closed on February 23, 1996, expanding the company into the wound care market.
- Liquidity Strategy: In March 1996, the company consummated an equity offering to eliminate indebtedness. The credit facility was amended to a $60 million revolving line of credit.
- Legal Contingencies: The company paid a $2.1 million patent infringement award in 1995 (accrued in 1993). It is currently defending patent challenges in the UK, Germany, and Japan regarding its Argon Beam Coagulation technology.
- Environmental: A subsidiary (Birtcher) is participating in an environmental investigation at a former facility; a reserve has been established, but no material adverse effect is expected.
- Regulatory: All products are subject to FDA regulation. The company relies on 510(k) clearances for new products.
Investor Verification Checklist
- Verify the integration success and revenue contribution of the Birtcher and Master Medical acquisitions.
- Confirm the closing details and financial impact of the New Dimensions in Medicine (NDM) acquisition.
- Monitor the status of international patent challenges regarding Argon Beam Coagulation technology.
- Review the company's ability to maintain gross margins as it integrates new product lines and faces competitive pricing pressures.
- Assess the impact of the March 1996 equity offering on share dilution and the reduction of interest expense.